C-terminus-outward orientation of SARS-CoV-2 envelope proteins on viral capsid enables a novel virus-cell interaction pathway.

阅读:3
作者:Xu Jie, Zhao Wei, Li Yuanyuan, Zheng Jing, Wang Yulian, Sun Huimin, Wu Sijin, Fu Baoqing, Wang Yiqiang
Since the onset of COVID-19, emphasis has been largely placed on spike proteins, while other molecules of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as the 78-aa-long envelope protein (E-pr), have been largely overlooked. This study was conducted to identify the orientation of E-pr in the envelope of the living SARS-CoV-2 virus and to confirm whether the viroid E-pr plays a role in the attachment and stimulation of the host cells. Using a customized antisera against the C-terminal half of E-pr (EC(38), 38 aa), we demonstrated that the EC(38) segment was located outside of the intact virus. Synthetic peptides with the sequence of the EC(38) segment were bound to and modulated gene expression in cultured human vascular endothelial cells (HUVECs), and altered genes were enriched for the ontology terms "hemostasis" and "regulation of systemic arterial blood pressure by hormone." EC(38)-mediated pull-down of HUVEC membrane proteins plus mass spectrometry revealed that the EC(38)-interacting proteins were enriched for "actin cytoskeleton organization," "cell-cell interaction," "cell-cell adhesion," "hemostasis," "viral infection pathways," "cytokine signaling in immune system," etc., among which CKAP4, vimentin, and ATP5B were further identified to bind EC(38) peptides. Molecular docking supported the potential binding of the E-pr with the ATP synthase. In summary, by displaying a C-terminal-outward orientation on the surface of the SARS-CoV-2 virus, E-pr was able to adhere to and stimulate host cells. Future studies should address whether the E-pr pathway could be utilized as a target for managing SARS-CoV-2 infection in humans.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。